Embodied Intelligence Observer

歌礼制药半年亏3.2亿:押注GLP‑1赛道,烧钱阵痛与专利风险双双袭来丨看财报

Industry

Source: 钛媒体Publish time unverified

核心候选药ASC30正遭遇石药专利挑战。

歌礼制药半年亏3.2亿:押注GLP‑1赛道,烧钱阵痛与专利风险双双袭来丨看财报 | Embodied Intelligence Observer